Clinical trials - Press Releases

Date	Title	Company
25-Jan-2022	FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy	PTC Therapeutics
20-Jan-2022	ABIVAX’S PHASE 1/2 CLINICAL STUDY RESULTS OF ABX196 IN LIVER CANCER TO BE PRESENTED ON JAN. 21, AT ASCO GI CANCERS SYMPOSIUM 2022	Abivax SA
20-Jan-2022	HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China	HUTCHMED
20-Jan-2022	The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia	Idorsia
19-Jan-2022	Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis	Sanofi
19-Jan-2022	Three Companies Join Forces to Become Centricity Research, North America’s Largest lntegrated Research Site Organization	Centricity Research
18-Jan-2022	New Phesi global analysis shows breast cancer was the most extensively studied disease area in 2021	Phesi
18-Jan-2022	Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022	Avance Clinical
13-Jan-2022	Spago Nanomedicals phase 1 study with SpagoPix shows clear contrast enhancement and is expanded into new indications	Spago Nanomedical AB
13-Jan-2022	Captario Has Been Selected by Alnylam Pharmaceuticals To Optimize Their Portfolio Management Process	Captario AB
12-Jan-2022	OncoHost Announces Interim Results from PROPHETIC Trial, Multicenter Assessment of NSCLC Patient Response to Immunotherapy	OncoHost
09-Jan-2022	Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coast 2022	SMi Group
07-Jan-2022	The Transdermal and Microneedle Drug Delivery Virtual Conference 2022 is now only 3 weeks away!	SMi Group
05-Jan-2022	B-cell lymphoma clinical trials now open on the TrialWire Platform	TrialWire
05-Jan-2022	Autism clinical trials now open on the TrialWire Platform	TrialWire
05-Jan-2022	ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen	ProQR Therapeutics N.V.
23-Dec-2021	MHRA approves licence extension for Novartis’ targeted therapy for advanced breast cancer patients in Great Britain	Novartis
23-Dec-2021	Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalised pustular psoriasis	Boehringer Ingelheim
21-Dec-2021	Medigene AG: Medigene achieves positive preliminary results in Phase I of Phase I/II trial of TCR-T therapy MDG1011 in blood cancers	Medigene AG
21-Dec-2021	Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®	Vifor Pharma